銀屑病是一種常見的以表皮過度增生為特征的慢性復(fù)發(fā)性非感染性炎癥性的皮膚??；也是一種在多基因遺傳背景下，由多種致病因子刺激機體免疫系統(tǒng)而引起的由T細胞介導為主的免疫相關(guān)性自身免疫紊亂性皮膚病。該病病因復(fù)雜，病程較長，且易反復(fù)發(fā)作。雖治療藥物繁多，療法多樣，但療效并不能確定，目前仍以改善患者癥狀為主。從生物制劑治療的角度，對其臨床相關(guān)的研究進展進行系統(tǒng)歸納總結(jié)，以期為其臨床治療提供參考。

Psoriasis is a common skin disease with chronic, recurrent, noninfectious, and inflammatory phenomenon, characterized by skin excessive proliferation. In the polygenic inheritance background, it is also an immune associated autoimmune disorders skin disease caused by T cell-mediated, which is caused by a variety of pathogenic factors to stimulate the body's immune system. The causes of the disease are complex. The course of the disease is long, and the recurrent attacks of the disease are easy. Therapeutic drugs are various and the treatment is diverse, but the curative effect is not sure. Therefore the treatment is still given priority to improve the symptoms of the patients. This paper, respectively from the perspective of biological drugs, systematically summarizes the research progress in the biological agents for the treatment of psoriasis, in order to lay the foundation for the clinical treatment.

天津市應(yīng)用基礎(chǔ)與前沿技術(shù)研究計劃重點項目（14JCZDJC33500）